Subscribe to RSS
DOI: 10.1055/s-0029-1217981
An Efficient Microwave-Promoted Route to (Z)-Stilbenes from trans-Cinnamic Acids: Synthesis of Combretastatin A-4 and Analogues
Publication History
Publication Date:
25 September 2009 (online)
Abstract
cis-Stilbenes were synthesized from trans-cinnamic acids, involving ethylenic-bond bromination and a subsequent one-pot microwave-promoted stereoselective debrominative decarboxylation-Suzuki cross-coupling strategy. This sequence represents a useful way to prepare a variety of combretastatin A-4 derivatives.
Key words
cis-stilbenes - cinnamic acids - combretastatin A-4 - debrominative decarboxylation - Suzuki-Miyaura cross-coupling reaction
- 2
Pettit GR.Singh SB.Hamel E.Lin CM.Alberts DS.Garcia-Kendall D. Experientia 1989, 45: 209 -
3a
Pettit GR.Singh SB.Niven ML.Hamel E.Schmidt JM. J. Nat. Prod. 1987, 50: 119 -
3b
Pettit GR.Singh SB.Boyd MR.Hamel E.Pettit RK.Schmidt JM.Hogan F. J. Med. Chem. 1995, 38: 1666 -
3c
Gaukroger K.Hadfield JA.Hepworth LA.Lawrence NJ.McGown AT. J. Org. Chem. 2001, 66: 8135 -
3d
Hsieh H.-P.Liou J.-P.Lin Y.-T.Mahindroo N.Chang J.-Y.Yang Y.-N.Chern S.-S.Tan U.-K.Chang C.-W.Chen T.-W.Lin C.-H.Chang Y.-Y.Wang C.-C. Bioorg. Med. Chem. Lett. 2003, 13: 101 - 4
Chaudhary A.Pandeya SN.Kumar P.Sharma PP.Gupta S.Soni N.Verma KK.Bhardwaj G. Mini-Rev. Med. Chem. 2007, 12: 1186 -
5a
Patterson DM.Rustin GJS. Clin. Oncol. 2007, 19: 443 -
5b
Lippert JW. Bioorg. Med. Chem. 2007, 15: 605 -
5c
Hinnen P.Eskens FALM. Br. J. Cancer 2007, 96: 1159 -
5d
Cai SX. Recent Pat. Anti-Cancer Drug Discov. 2007, 2: 79 - 6
West CML.Price P. Anti-Cancer Drugs 2004, 15: 179 - 7
Horsman MR.Siemann DW. Cancer Res. 2006, 66: 11520 -
8a
Nam N.-H. Curr. Med. Chem. 2003, 10: 1697 -
8b
Hsieh H.-P.Liou J.-P.Mahindroo N. Curr. Pharm. Des. 2005, 11: 1655 -
8c
Tron GC.Pirali T.Sorba G.Pagliai F.Busacca S.Genazzani AA. J. Med. Chem. 2006, 49: 3033 -
8d
Mahindroo N.Liou J.-P.Chang J.-Y.Hsieh H.-P. Expert Opin. Ther. Pat. 2006, 16: 647 -
9a
Davis PD. inventors; WO 200112579. -
9b
Seyedi F,Gale J,Haider R,Hoare J, andBaldwin A. inventors; WO 2002006279. -
9c
Mutti S,Lavigne M,Malejonock I, andCasimir J.-P. inventors; WO 2003084919. -
9d
Maya ABS.Pérez-Melero C.Mateo C.Alonso D.Fernández JL.Gajate C.Mollinedo F.Peláez R.Caballero E.Medarde M. J. Med. Chem. 2005, 48: 556 -
9e
Pettit GR.Rhodes MR.Herald DL.Hamel E.Schmidt JM.Pettit RK. J. Med. Chem. 2005, 48: 4087 -
9f
Simoni D,Romagnoli R,Giannini G,Alloati D, andPisano C. inventors; WO 2005007635. -
9g
Chang J.-Y.Yang M.-F.Chang C.-Y.Chen C.-M.Kuo C.-C.Liou J.-P. J. Med. Chem. 2006, 49: 6412 -
9h
Harrowven DC.Guy IL.Howell M.Packham G. Synlett 2006, 2977 -
10a
Lindlar H.Dubuis R. Org. Synth. 1966, 46: 89 ; Org. Synth., Coll. Vol. V, 1973, 880 -
10b
Fürstner A.Nikolakis K. Liebigs Ann. Chem. 1996, 12: 2107 -
10c
Lawrence NJ.Ghani FA.Hepworth LA.Hadfield JA.McGown AT.Pritchard RG. Synthesis 1999, 1656 -
10d
Wei L.-L.Wei L.-M.Pan W.-B.Leou S.-P.Wu M.-J. Tetrahedron Lett. 2003, 44: 1979 -
10e
Nakamura H.Kuroda H.Saito H.Suzuki R.Yamori T.Maruyama K.Haga T. ChemMedChem 2006, 1: 729 -
10f
Lara-Ochoa F.Espinosa-Pérez G. Tetrahedron Lett. 2007, 48: 7007 -
10g
Giraud A.Provot O.Hamzé A.Brion J.-D.Alami M. Tetrahedron Lett. 2008, 49: 1107 -
11a
Hadfield JA,McGown AT,Gaukroger K,Hepworth LA, andLawrence NJ. inventors; WO 200249994. -
11b
Katayama H.Nagao M.Ozawa F.Ikegami M.Arai T. J. Org. Chem. 2006, 71: 2699 -
11c
Wakioka M.Nagao M.Ozawa F. Organometallics 2008, 27: 602 - 12
Uenishi J.Kawahama R.Shiga Y.Yonemitsu O.Tsuji J. Tetrahedron Lett. 1996, 37: 6759 - 13
Kuang C.Senboku H.Tokuda M. Tetrahedron Lett. 2001, 42: 3893 ; and references cited therein - 14
Bazin M.-A.El Kihel L.Lancelot J.-C.Rault S. Tetrahedron Lett. 2007, 48: 4347 - 15
Del Ponte G.Costa Arcanjo F.Botteghi C. J. Mol. Catal. A: Chem. 2003, 192: 35 - 16
Kuang C.Yang Q.Senboku H.Tokuda M. Tetrahedron 2005, 61: 4043 - For example, see:
-
17a
Cushman M.Nagarathnam D.Gopal D.Chakraborti AK.Lin CM.Hamel E. J. Med. Chem. 1991, 34: 2579 -
17b
Cushman M.Nagarathnam D.Gopal D.He H.-M.Lin CM.Hamel E. J. Med. Chem. 1992, 35: 2293 -
17c
Medarde M.Ramos A.Caballero E.Peláez-Lamamié de Clairac R.López JL.Grávalos DG.San Feliciano A. Eur. J. Med. Chem. 1998, 33: 71 -
17d
Hatanaka T.Fujita K.Ohsumi K.Nakagawa R.Fukuda Y.Nihei Y.Suga Y.Akiyama Y.Tsuji T. Bioorg. Med. Chem. Lett. 1998, 8: 3371 -
17e
Gaukroger K.Hadfield JA.Lawrence NJ.Nolan S.McGown AT. Org. Biomol. Chem. 2003, 1: 3033 - For Suzuki-Miyaura cross-coupling reactions using K3PO4 as base in DMF, see:
-
18a
Watanabe T.Miyaura N.Suzuki A. Synlett 1992, 207 -
18b
Cailly T.Fabis F.Rault S. Tetrahedron 2006, 62: 5862
References and Notes
Current address: Université de Nantes, Nantes Atlantique Universités, IICiMed EA1155, UFR des Sciences Pharmaceutiques, Laboratoire de Chimie Thérapeutique, 1 Rue Gaston Veil, BP 53508, 44000 Nantes, France.
19
General Procedure
for the One-Pot Synthesis of 5a-n
In a 10
mL microwave vial were introduced a magnetic stir bar, a anti-2,3-dibromo-3-arylpropanoic acid 2 (5.0 mmol, 1.00 equiv), and Et3N
(1.05 equiv) in DMF (1 mL). The vial was sealed, and the suspension
was then heated at 140 ˚C for 1 min. After CO2 removal
were added a boronic acid 4 (1.20 equiv),
K2CO3 (2.50 equiv) or NaOH (3.50 equiv), Pd(PPh3)4(0.05 equiv), and DME-H2O (2:1, 8 mL).
The vial was sealed and purged with argon through the septum inlet.
The suspension was then heated at 100 ˚C for 15
min. The resulting mixture was acidified with 1 N HCl. H2O
and Et2O were added, and the aqueous layer was extracted
with Et2O (3 × 30 mL). The
combined organic layers were washed with H2O, dried over
MgSO4, filtered, and evaporated. The crude product was
then purified by silica gel chromatography (eluent: cyclohexane-EtOAc)
to afford (Z)-stilbene 5 as
a pure compound. Compound trans-5 was isolated too, to determine the Z/E ratio.
Selected Data
Compound 5d: orange solid; yield 0.51 g (63%);
mp 78 ˚C. IR (KBr): ν = 2931,
2831, 1581, 1510, 1487, 1454, 1330, 1235, 1129, 1024, 1006, 846
cm-¹. ¹H NMR (400
MHz, CDCl3): δ = 3.71
(s, 6 H, 2 × OMe), 3.85 (s, 3 H, OMe),
5.92 (s, 2 H, OCH2O), 6.42 (d, J = 11.7
Hz, 1 H, =CH), 6.48 (d, J = 11.7
Hz, 1 H, =CH), 6.51 (s, 2 H, Har), 6.73 (d, J = 8.8 Hz,
1 H, Har), 6.79-6.81 (m, 2 H, Har). ¹³C
NMR (100 MHz, CDCl3): δ = 55.9
(2 C, 2 × OMe), 60.9 (OMe), 100.9, 105.9 (2
C), 108.1, 109.0, 122.9, 129.1, 129.4, 131.1, 132.5, 137.1, 146.6,
147.3, 152.9 (2 C). ESI-MS: m/z = 315 [M + H]+. HRMS
(EI): m/z calcd for C18H18O5:
314.1154; found: 314.1165.
Compound 5m:
yellow solid; yield 0.17 g (45%); mp 58 ˚C. IR
(KBr): ν = 3417, 2956, 1605, 1511, 1465, 1274,
1241, 1175, 1029, 870 cm-¹. ¹H
NMR (400 MHz, CDCl3): δ = 3.67 (s,
3 H, OMe), 3.79 (s, 3 H, OMe), 5.58 (s, 1 H, OH), 6.42 (part A of
AB system, ³
J
AB = 11.7
Hz, 1 H, =CH), 6.45 (part B of AB system, ³
J
AB = 11.7
Hz, 1 H, =CH), 6.77-6.79 (m, 5 H, Har),
7.22 (d, J = 8.8
Hz, 1 H, Har). ¹³C NMR (100
MHz, CDCl3): δ = 55.2
(OMe), 55.7 (OMe), 111.1, 113.5, 114.1, 122.4, 126.1, 127.4, 128.3,
128.7, 130.1, 144.7, 146.0, 158.5. ESI-MS: m/z = 257 [M + H]+.
HRMS (EI): m/z calcd for C16H16O3:
256.1099; found: 256.1109.